| Literature DB >> 29446839 |
Jiawen Zheng1, Zhuosi Li1, Yuki Manabe1, Minji Kim2, Tsuyoshi Goto2, Teruo Kawada2, Tatsuya Sugawara1.
Abstract
Nonalcoholic fatty liver disease (NAFLD) has shown an increasing morbidity in recent years. Here, we demonstrated that siphonaxanthin (SPX), a rare marine carotenoid, exhibits a strong inhibitory effect on aggravated hepatic lipogenesis in vitro and would be a promising candidate in the prevention and alleviation of NAFLD in the future. In this study, we conducted a preliminary assessment of the effect of SPX on hepatic lipogenesis by using the HepG2 cell line, derived from human liver cancer, as a model of the liver. SPX significantly suppressed the excess accumulation of triacylglycerol induced by liver X receptor α (LXRα) agonist by downregulating a nuclear transcription factor named sterol regulatory element-binding protein-1c and a set of related genes. Moreover, fatty acid translocase (CD36) and fatty acid-binding protein-1, which regulates fatty acid uptake, also exhibited significant decrease in transcriptional levels. Furthermore, we found that SPX blocked LXRα activation and would be a promising candidate for antagonist of LXRα.Entities:
Keywords: Carotenoid; LXRα; SREBP-1c; hepatocyte; lipogenesis; siphonaxanthin
Mesh:
Substances:
Year: 2018 PMID: 29446839 DOI: 10.1002/lipd.12002
Source DB: PubMed Journal: Lipids ISSN: 0024-4201 Impact factor: 1.880